India’s Biotech Renaissance: Dr. Jogin Desai Forecasts Breakthrough Therapies Every Two Years

eyestem eyecyte rpe

India is transitioning from a global manufacturing hub to a leader in deeptech innovation. In this featured interview, Dr. Jogin Desai, CEO of Eyestem, explores how a compressed therapy timeline, the ₹10,000 crore Biopharma SHAKTI programme, and a focus on “reversing” rather than just “slowing” diseases are positioning India to deliver life-changing medical solutions to the world at a fraction of the traditional cost.

Three Person IVF: UK Welcomes Healthy Babies, Preventing Transmission of Genetic Disease

baby feet

Eight healthy babies have been born in the UK using a revolutionary “three-person IVF” technique called mitochondrial donation. This groundbreaking procedure, led by scientists at Newcastle University, successfully prevents the transmission of incurable, inherited genetic diseases from mother to child, offering new hope to families worldwide.

Trastuzumab: Targeted Therapy for HER2-Positive Cancers – Details, Mechanism, Usage and Side Effects

trastuzumab structure

Trastuzumab is a monoclonal antibody that has been engineered to attack and block the human epidermal growth factor receptor 2 (HER2), a protein that contributes to cancer cell growth. It is used most frequently to treat HER2-positive breast cancer and HER2-positive gastric cancer. As [Read More…]

Effective Drug Development Using Fewer Mice

mice in clinical tests

New active components, such as antibodies, are often evaluated separately in laboratory animals. Researchers at UZH have now created a method that can test up to 25 antibodies in a single mouse. This could not only accelerate the research and development pipeline for new pharmaceuticals, but also significantly reduce the number of experimental animals needed.